Item 4.01 Changes in Registrant's Certifying Accountant.
The Board of Directors (the “Board”) of Cumberland Pharmaceuticals Inc. (the "Company") and its Audit Committee (the “Audit Committee”), have completed a review of the appointment of the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.
On May 18, 2023, the Company informed FORVIS, LLP (“FORVIS”) of its decision to not retain FORVIS as the Company's independent registered public accounting firm. In addition, the Company informed Carr, Riggs & Ingram, LLC (“CRI”) that they were selected as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. CRI had obtained provisional approval, with their appointment to become effective upon the execution of an engagement letter and related completion of CRI's final client acceptance procedures.
During the Company's fiscal years ended December 31, 2022 and 2021, and the subsequent interim period through May 18, 2023, there were (i) no “disagreements” (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and FORVIS on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to FORVIS’s satisfaction, would have caused FORVIS to make reference to the subject matter of the disagreement in its report on the Company's consolidated financial statements for the relevant year, and (ii) no "reportable events" as that term is defined in Item 304(a)(1)(v) of Regulation S-K. The audit reports of FORVIS on the consolidated financial statements of the Company as of December 31, 2022 and 2021, contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.
The Company has provided FORVIS with a copy of the disclosures in this Current Report on Form 8-K and requested FORVIS to, as promptly as possible, furnish the Company with a letter (the "FORVIS Letter") addressed to the Securities and Exchange Commission (“SEC”) stating whether FORVIS agrees with the statements made by the Company in response to Item 304(a) of Regulation S-K and, if not, stating the respects in which it does not agree. FORVIS has furnished the Company a letter addressed to the SEC. That letter is attached to this Current Report on Form 8-K as Exhibit 16.1.
During the Company's fiscal years ended December 31, 2022 and 2021, and the subsequent interim period through May 18, 2023, neither the Company, nor anyone on its behalf, consulted with CRI regarding (i) the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on the Company's consolidated financial statements, and neither a written report nor oral advice was provided to the Company that CRI concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a “disagreement” (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a “reportable event” (as that term is defined in Item 304(a)(1)(v) of Regulation S-K).